Benjamin M Morin

US Patent:

20230014036, Jan 19, 2023

Filed:

Aug 10, 2022

Appl. No.:

17/818840

Inventors:

- Lexington MA, US
Zahra Jawad - Lexington MA, US
Olga Ignatovich - Lexington MA, US
Nicola Anne Ramsay - Lexington MA, US
Spencer Campbell - Lexington MA, US
Beth Wensley - Lexington MA, US
Emmanuel Cyrille Pascal Briend - Lexington MA, US
K. Mark Bushell - Lexington MA, US
Benjamin Maxime Morin - Lexington MA, US
Veronica Franciszka Ilkow - Lexington MA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.